Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine, Cyclophosphamide, and Rituximab in Chronic Lymphocytic Leukemia (Phase II)
2008-001250-40Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Cancer Trials Ireland. Primary endpoint: Complete remission rate by NCI criteria and MRD. Started Mar 2008; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-001250-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001250-40.